Analyst: Lilly doesn't overshadow semaglutide in spite of strong data
Even though Eli Lilly presented strong data in a comparison study between this company's drug tirzepatide and Novo Nordisk's rival semaglutide, it'll take more to eliminate the Danish competition, according to an analyst.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Thursday, US pharmaceutical firm Eli Lilly has presented convincing data in favor of the drug candidate tirzepatide, which is a GLP-1 analog.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst emphasizes 2021 guidance in Genmab fiscal report
For subscribers
